Ipsen SA (IPN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH15876FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ipsen SA (IPN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in few countries. It main research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Apr 01,2021: Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Feb 11,2021: Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Jan 20,2021: Ipsen appoints Gwenan White as executive Vice President, Communications and Public Affairs
Dec 01,2020: Ipsen highlights new strategic priorities and provides mid-term financial outlook
Oct 22,2020: Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ipsen SA – Key Facts
Ipsen SA – Key Employees
Ipsen SA – Key Employee Biographies
Ipsen SA – Major Products and Services
Ipsen SA – History
Ipsen SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Ipsen SA – Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Business Segment: Other Revenues
Performance
Business Segment: Specialty Care
Overview
Performance
Geographical Segment: Major Western European Countries
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other European Countries
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
R&D Overview
Ipsen SA – Corporate Strategy
Ipsen SA – SWOT Analysis
SWOT Analysis – Overview
Ipsen SA – Strengths
Ipsen SA – Weaknesses
Ipsen SA – Opportunities
Ipsen SA – Threats
Ipsen SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ipsen SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 11, 2021: Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Jan 20, 2021: Ipsen appoints Gwenan White as executive Vice President, Communications and Public Affairs
Dec 01, 2020: Ipsen highlights new strategic priorities and provides mid-term financial outlook
Oct 22, 2020: Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
Oct 05, 2020: FAS RUSSIA: Ipsen unreasonably refused Biotek to conclude contract for medicine supply
Sep 25, 2020: Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer
Jul 30, 2020: Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
Jul 01, 2020: David Loew joins Ipsen as CEO
Jun 08, 2020: Ipsen demonstrates continued commitment to rare diseases with eight abstracts accepted at ENDO 2020 published in the Journal of the Endocrine Society
May 29, 2020: Ipsen appoints David Loew as chief executive officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont...1)
Ipsen SA, Annual Ratios (Cont...2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ipsen SA (IPN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Smith & Nephew Plc (SN.):医療機器:M&Aディール及び事業提携情報
    Summary Smith & Nephew Plc (Smith & Nephew) is a medical technology company that develops, manufactures and markets medical devices for use in orthopaedic reconstruction and trauma, sports medicines and advanced wound management. The company offers its products in various categories including Sports …
  • Celsion Corp (CLSN)-製薬・医療分野:企業M&A・提携分析
    Summary Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (L …
  • Cargotec Oyj:企業のM&A・事業提携・投資動向
    Cargotec Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cargotec Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Tereos:企業の戦略・SWOT・財務情報
    Tereos - Strategy, SWOT and Corporate Finance Report Summary Tereos - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Les Laboratoires Servier SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Les Laboratoires Servier SAS (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company's portfolio of marketed products treat central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, women's …
  • Citigroup Inc:企業の戦略・SWOT・財務情報
    Citigroup Inc - Strategy, SWOT and Corporate Finance Report Summary Citigroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Akashi Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Akashi Therapeutics Inc (Akashi Therapeutics), formerly DART Therapeutics Inc is a clinical stage biopharmaceutical company develops treatment for duchenne muscular dystrophy (DMD) and other rare pediatric diseases. The company provides pipeline portfolio such as HT-100, a small molecule dru …
  • Aesica Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Aesica Pharmaceuticals Ltd (Aesica), a subsidiary of Consort Medical plc is a contract development and manufacturing organization (CDMO). It manufactures and develops generic active pharmaceutical ingredients (APIs) and finished dosage forms. Aesica’s services portfolio encompass pre-formula …
  • Oncobiologics Inc (ONS):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncobiologics Inc (Oncobiologics) is a clinical stage biopharmaceutical company that identifies, develops, manufactures and commercializes biosimilar therapeutics in the areas of immunology and oncology. The company's pipeline products include ONS-3010, an adalimumab biosimilar intended for …
  • Insightra Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Insightra Medical Inc (Insightra Medical), a subsidiary of GPB Life Science Holdings LLC is a medical device company that develops disposable devices. The company provides cardiovascular and surgical solutions. It offers cardiovascular solutions such as Ultra 7FR IAB and modulare. The Modula …
  • Ramsay Health Care Ltd (RHC):製薬・医療:M&Aディール及び事業提携情報
    Summary Ramsay Health Care Ltd (RHC) is a global healthcare group that owns and operates through healthcare facilities. Its facilities cater for a range of health care needs from day surgery procedures to complex surgeries. The company also provides psychiatric care and rehabilitation services. RHC …
  • Brake Bros Limited:企業の戦略的SWOT分析
    Brake Bros Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Correvio Pharma Corp (CORV):企業の財務・戦略的SWOT分析
    Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bayer AG:企業の戦略・SWOT・財務情報
    Bayer AG - Strategy, SWOT and Corporate Finance Report Summary Bayer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Calpine Corporation (CPN)-エネルギー分野:企業M&A・提携分析
    Summary Calpine Corporation (Calpine) is an electric and natural gas utility. The company produces electricity and thermal energy from natural gas, geothermal, and solar sources. It uses natural gas-fired combustion and renewable geothermal conventional steam turbine technologies to generate energy. …
  • QT Holdings Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary QT Holdings Corp, d.b.a Quad Technologies, a subsidiary of Bio Techne Corp, is a life sciences company that strives to develop bioprocessing reagents for cell-based therapeutics. The company offers QuickGel, a biocompatible dissolvable polymer technology, for cell separation and activation. …
  • Gamma Medica Inc:医療機器:M&Aディール及び事業提携情報
    Summary Gamma Medica Inc (Gamma Medica), formerly Gamma Medica Ideas Inc is a medical device company that offers imaging solutions. The company designs, develops and manufactures imaging systems for clinical and pre-clinical applications. It offers lumagem, lumagem mbi workflow, lumagem procedure ov …
  • SilverSun Technologies Inc (SSNT):企業の財務・戦略的SWOT分析
    Summary SilverSun Technologies Inc (SilverSun) is a technology company that offers transformational business technology solutions and services for manufacturers and distributors. The company’s ERP software products comprise ERP X3, MAS90 and MAS200. It offers network services such as 24/7 remote net …
  • Seair Inc:企業の戦略的SWOT分析
    Seair Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Perenco Holdings:石油・ガス:M&Aディール及び事業提携情報
    Summary Perenco Holdings (Perenco) is an independent upstream energy company. It explores for, develops, produces, transports, and stores oil and gas. The company’s oil fields ranges from Northern Europe to Africa and Latin America to Southeast Asia. Through spot sales and long term sales agreements …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆